Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>The proliferation of pulmonary arterial smooth muscle cells (PASMCs) and subsequent pulmonary vascular remodeling leads to pulmonary arterial hypertension (PAH). Understanding the underlying mechanisms and identifying molecules that can suppress PASMCs proliferation is critical for developing effective pharmacological treatment. We previously showed that plasminogen activator inhibitor-2 (PAI-2) inhibited human PASMC (hPASMCs) proliferation <em>in vitro</em>. However, its inhibitory effect on PAH remains to be determined, and the mechanism remains to be illustrated.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We compared serum PAI-2 levels between PAH patients and healthy controls, and examined the correlation between PAI-2 level and disease severity. In monocrotaline-induced PAH rats, we examined the effects of exogenous PAI-2 administration on pulmonary vascular remodeling and PAH development. The effect of PAI-2 and potential mechanisms was further examined in cultured hPASMCs.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>The serum PAI-2 was decreased in PAH patients compared with controls. PAI-2 level was negatively correlated with mean pulmonary arterial pressure and estimated systolic pulmonary arterial pressure in ultrasonic cardiogram, while positively correlated with 6-min walking distance. In rats, administration of exogenous PAI-2 significantly reversed monocrotaline-induced PAH, as indicated by the decrease in right ventricle systolic pressure, right ventricular hypertrophy index and percent media thickness of pulmonary arterioles. Further mechanistic investigation in hPASMCs showed that PAI-2 inhibited cell proliferation by preventing the activation of PI3K/Akt and ERK pathways.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>PAI-2 is downregulated in PAH patients. PAI-2 attenuates PAH development by suppressing hPASMCs proliferation via the inhibition of PI3K/Akt and ERK pathways. PAI-2 may serve as a potential biomarker and therapeutic target for PAH.</p>

Research Progress of Plasminogen Activator Inhibitor-1 in Several Diseases

Three Decades of Research on Plasminogen Activator Inhibitor-1: A Multifaceted Serpin

The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo

Targeting Plasminogen Activator Inhibitor-1 to Prevent Vascular Disease

Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1)

Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition

Plasminogen activator inhibitor-1 inhibitors: a patent review (2006 – present)

A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?

Functional Stability of Plasminogen Activator Inhibitor-1

Importance of Fibrinolytic Activity in Patients with Coronary Artery Diseases

Novel Distribution Pattern of Fibrinolytic Components in Rabbit Tissues Extract: a Preliminary Study

Good or bad: Paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumors

Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma: Its Role in Thrombotic Disease

A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease

The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis

Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension via PI3K/Akt and ERK signaling

Genome-wide Association Study for Circulating Levels of Plasminogen Activator Inhibitor-1 (PAI-1) Provides Novel Insights into the Regulation of PAI-1 Running Title: HUANG Et Al., GENETIC LOCI ASSOCIATED WITH PAI-1

Orchestra of ligand-activated transcription factors in the molecular symphony of SERPINE 1 / PAI-1 gene regulation

The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding

PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA

[Inhibitor of Plasminogen Activator 1 (PAI-1) in Hepatocellular Carcinoma].